Help us find out if we can protect people against symptoms caused by the norovirus stomach bug with an investigational mRNA vaccine.
Norovirus is one of the most common causes of stomach bugs in the UK. There is currently no vaccine to protect against norovirus infection.
The Nova 301 Trial is looking to recruit approximately 25,000 people globally to help see if an investigational mRNA vaccine can protect people against the symptoms caused by the norovirus stomach bug.
Researchers at our hubs in Portsmouth, Bournemouth and Weymouth are recruiting people to take part in this new clinical trial to see if an investigational vaccine (a vaccine that is being studied) may be able to protect people 18 years of age or older against the symptoms caused by the norovirus stomach bug. The investigational vaccine will be compared to a placebo jab (an inactive substance).
The Nova 301 Trial is a Phase 3 clinical trial. This is the last phase before an investigational vaccine can be made available for public use (after approval from the UK Medicines and Healthcare products Regulatory Agency). Phase 3 trials like this one evaluate the investigational vaccine in a large group of people.
People taking part in the Nova 301 Trial must be 18 years of age or over, be in good health and should not currently have a chronic gastrointestinal disease (including irritable bowel syndrome, colitis, oesophageal reflux, or any other medical condition with regular vomiting or diarrhoea).
Participants will receive either the investigational vaccine or a placebo jab (an inactive substance).
The trial will last for up to 25 months, and participants must be willing to attend up to 7 scheduled clinic visits over that time.
More information is available from your nearest hub teams.
Portsmouth Research Hub
023 9228 6236
Bournemouth Research Hub
0300 019 6686
Weymouth Research Hub
01305 362025
The Nova 301 Trial team will be on hand to support everyone who takes part in the trial. They will also make sure that participants understand the important details about the trial before agreeing to take part. This is called informed consent and includes what the trial involves and any risks.
Moderna, the company who has developed the investigational vaccine and the Nova 301 Trial programme, will reimburse participants for their trial-related time and expenses, for example, travel.
Doctor Patrick Moore, co-director of Wessex Research Hubs and Chief Investigator of the trial in the UK, said: “We are really pleased to be able to play an important role in helping find an effective vaccine against this highly contagious disease. Outbreaks of norovirus have huge consequences, both on our health systems and our economy. If you’re interested in helping us advance healthcare, please do come forward to take part in this innovative trial.”
References:
NHS Inform. Norovirus. Accessed June, 2024. https://www.nhsinform.scot/illnesses-and-conditions/infections-and-poisoning/norovirus/
Zhang, X. et al. Global Burden and Trends of Norovirus-Associated Diseases From 1990 to 2019: An Observational Trend Study. Front. Public Health. 2022 Jun 17;10:905172. doi: 10.3389/fpubh.2022.905172.
Moderna has provided editorial support for this article.
Comments